Plasma aldosterone levels during hospitalization are predictive of survival post-myocardial infarction

European Heart Journal

Volumn 29, Issue 20, 2008, Pages 2489-2496

  Palmer, Barry R ^a   Pilbrow, Anna P ^a   Frampton, Christopher M ^a   Yandle, Tim G ^a   Skelton, Lorraine ^a   Nicholls, M Gary ^a   Richards, A Mark ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Aldosterone; Hormones; Mortality; Myocardial infarction; Prognosis

Indexed keywords

ADRENALIN; ALDOSTERONE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTILIPEMIC AGENT; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN 1; FIBRINOLYTIC AGENT; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ADRENALIN BLOOD LEVEL; ADULT; ADVERSE OUTCOME; ALDOSTERONE BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETES MELLITUS; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DYSLIPIDEMIA; ETHNICITY; FEMALE; HAZARD RATIO; HEART INFARCTION; HOSPITALIZATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; POSTOPERATIVE CARE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVASCULARIZATION; SMOKING; ST SEGMENT ELEVATION; SURVIVAL TIME; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT DURATION;

ALDOSTERONE; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; FEMALE; FOLLOW-UP STUDIES; HOSPITAL MORTALITY; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; REGRESSION ANALYSIS; SURVIVAL ANALYSIS;

EID: 54149092408     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehn383     Document Type: Article

References (28)

1. Funder JW. The nongenomic actions of aldosterone. Endocr Rev 2005;26:313-321.
2. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-1321.
3. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-717.
4. Beygui F, Collet JP, Benoliel JJ, Vignolles N, Dumaine R, Barthelemy O, Montalescot G. High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction. Circulation 2006;114:2604-2610.
5. Richards AM, Nicholls MG, Yandle TG, Ikram H, Espiner EA, Turner J, Buttimore R, Lainchbury JG, Elliott J, Frampton CM, Crozier I, Smyth D. Neuroendocrine prediction of left ventricular function and heart failure after acute myocardial infarction. Heart 1999;81:114-120.
6. Richards AM, Nicholls MG, Espiner EA, Lainchbury JG, Troughton RW, Elliott J, Frampton C, Turner J, Crozier IG, Yandle TG. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation 2003;107:2786-2792.
7. Lun S, Espiner EA, Nicholls MG, Yandle TG. A direct radioimmunoassay for aldosterone in plasma. Clin Chem 1983;29:268-271.
8. Rademaker MT, Cameron VA, Charles CJ, Espiner EA, Nicholls MG, Pemberton CJ, Richards AM. Neurohormones in an ovine model of compensated postinfarction left ventricular dysfunction. Am J Physiol Heart Circ Physiol 2000;278:H731-H740.
9. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
10. Ceremuzynski L. Hormonal and metabolic reactions evoked by acute myocardial infarction. Circ Res 1981;48:767-776.
11. Arora RB. Role of catecholamines, aldosterone, potassium and lipids in pathophysiology and severity of myocardial infarction-a clinical and experimental study. J Assoc Physicians India 1974;22:613-621.
12. Arora RB, Somani P. Ectopic arrhythmia provoking action of aldosterone. Life Sci 1962;1:215-218.
13. Nicod P, Waeber B, Brunner HR. Renin in myocardial infarction. In: Robertson JIS, Nicholls MG, ed. The Renin-Angiotensin System. London: Mosby; 1993. pp. 77.71-77.79.
14. Donald RA, Crozier IG, Foy SG, Richards AM, Livesey JH, Ellis MJ, Mattioli L, Ikram H. Plasma corticotrophin releasing hormone, vasopressin, ACTH and cortisol responses to acute myocardial infarction. Clin Endocrinol (Oxf) 1994;40:499-504.
15. Nicholls MG, Espiner EA, Donald RA. Plasma aldosterone response to low dose ACTH stimulation. J Clin Endocrinol Metab 1975;41:186-188.
16. Chai W, Garrelds IM, de Vries R, Batenburg WW, van Kats JP, Danser AH. Non-genomic effects of aldosterone in the human heart: interaction with angiotensin II. Hypertension 2005;46:701-706.
17. Wehling M. Rapid effects of aldosterone: relevant in cardiac ischemia? Hypertension 2005;46:27-28.
18. Young MJ, Lam EY, Rickard AJ. Mineralocorticoid receptor activation and cardiac fibrosis. Clin Sci (Lond) 2007;112:467-475.
19. Liu SL, Schmuck S, Chorazcyzewski JZ, Gros R, Feldman RD. Aldosterone regulates vascular reactivity: short-term effects mediated by phosphatidylinositol 3-kinase-dependent nitric oxide synthase activation. Circulation 2003;108:2400-2406.
20. Oberleithner H. Aldosterone makes human endothelium stiff and vulnerable. Kidney Int 2005;67:1680-1682.
21. Yee KM, Struthers AD. Aldosterone blunts the baroreflex response in man. Clin Sci (Lond) 1998;95:687-692.
22. Moudgil LR. Possible protective action of antialdosterone compounds in myocardial necrosis in rats. Br J Pharmacol 1969;35:558-562.
23. Delyani JA, Robinson EL, Rudolph AE. Effect of a selective aldosterone receptor antagonist in myocardial infarction. Am J Physiol Heart Circ Physiol 2001;281:H647-H654.
24. Mill JG, Milanez Mda C, de Resende MM, Gomes Mda G, Leite CM. Spironolactone prevents cardiac collagen proliferation after myocardial infarction in rats. Clin Exp Pharmacol Physiol 2003;30:739-744.
25. Fraccarollo D, Galuppo P, Hildemann S, Christ M, Ertl G, Bauersachs J. Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction. J Am Coll Cardiol 2003;42:1666-1673.
26. Takeda M, Tatsumi T, Matsunaga S, Hayashi H, Kimata M, Honsho S, Nishikawa S, Mano A, Shiraishi J, Yamada H, Takahashi T, Matoba S, Kobara M, Matsubara H. Spironolactone modulates expressions of cardiac mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase 2 and prevents ventricular remodeling in post-infarct rat hearts. Hypertens Res 2007;30:427- 437.
27. Modena MG, Aveta P, Menozzi A, Rossi R. Aldosterone inhibition limits collagen synthesis and progressive left ventricular enlargement after anterior myocardial infarction. Am Heart J 2001;141:41-46.
28. Hayashi M, Tsutamoto T, Wada A, Tsutsui T, Ishii C, Ohno K, Fujii M, Taniguchi A, Hamatani T, Nozato Y, Kataoka K, Morigami N, Ohnishi M, Kinoshita M, Horie M. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 2003;107:2559- 2565.